Cardiac Stem Cells Fail With Aging
A New Mechanism for the Age-Dependent Decline in Cardiac Function

Maurizio C. Capogrossi

Aging, even in apparently healthy individuals without overt cardiovascular disease, is associated with changes in heart structure and compromised cardiac reserve function. These changes per se do not lead to clinical heart failure; however, they make the heart more vulnerable to myocardial ischemia, systemic arterial hypertension, and other pathological conditions, thereby playing a major role in the markedly increased prevalence of heart failure in the elderly. Some of the mechanisms responsible for cardiac aging have been characterized both in humans and in animal models. Intimal thickening, enhanced arterial stiffness, and endothelial dysfunction target the arterial wall and, in due time, will have a negative effect on the structure and function of the heart. In addition, old myocardial cells are fewer and larger than those from younger hearts and exhibit a prolonged action potential and contraction duration, a diminished response to β-adrenergic stimulation, as well as other functional changes. The basic mechanism(s) that underlie cellular aging have not been conclusively established, but oxidative stress may be a key causal element. The study by Torella et al makes several important points concerning the effect of aging on CSCs: (1) stem cells were identified both in young and old hearts and their number increased with animal age, (2) the percentage of CSCs that exhibited evidence of senescence, ie, p16 expression, telomere shortening, and apoptosis, was higher in older animals, (3) the effect of aging on CSCs was largely attenuated in IGF-1 TG mice. Together with a study in endothelial cells, the work by Torella et al demonstrates that Akt constitutes a main modulator of telomerase activity in non-neoplastic or immortalized cells. Most importantly, phospho-Akt expression and the consequent regulation of telomerase declined with age. The age-dependent alteration of the telomerase-telomere system in myocytes and the shorter telomere length in CSCs from older mice are in agreement with an impaired proliferative potential of the amplifying myocyte compartment. Therefore, the age-dependent deterioration in cardiac function may be related, at least in part, to the failure of aged CSCs to replace dead myocytes with new functioning cells. Similar observations on the effect of aging to impair stem cell regenerative ability have also been made in other tissues. Interestingly, the age-dependent effects on heart function, on myocardial cells, and on CSCs were attenuated in IGF-1 TG mice. It is noteworthy that the effect of IGF-1 signaling in aging is still controversial. Both in Caenorhabditis elegans and in fruitflies, reduced activity of this pathway prolonged life. Further, IGF-1 receptor +/− mice exhibited an increased life span and enhanced resistance to oxidative stress. In contrast, results in agreement with those of Torella et al were obtained in skeletal muscle. IGF-1 overexpression extended regenerative capacity of aging skeletal muscle after injury and prevented age-related loss of muscle size and strength. These effects were, at least in part, attributable to satellite cell activity, ie, to skeletal muscle stem cells. Torella’s study opens a new area of work in aging cardiovascular research and raises many questions. Are age-dependent CSC changes a primary event or are they secondary to vascular changes or to other age-dependent modifications in heart structure?

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Laboratorio di Patologia Vascolare, Istituto Dermopatico dell’Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Correspondence to Maurizio C. Capogrossi, MD, Laboratorio di Patologia Vascolare, Istituto Dermopatico dell’Immacolata-IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy. E-mail capogrossi@idi.it (Circ Res. 2004;94:411-413.)

© 2004 American Heart Association, Inc.

Circulation Research is available at http://www.circresaha.org
DOI: 10.1161/01.RES.0000122070.37999.1B
The relative contribution of the decrease in CSC proliferation potential versus the decreased functional properties of old myocytes and the vascular changes with respect to the age-associated decline in myocardial function remains unknown.

Do IGF-1 TG animals have an extended life span and, eventually, develop changes in cardiac function, myocardial cell size, CSC number, and expression of senescence markers, at a later chronological age than control mice?

Are CSCs resident in the heart from birth or do these cells originate from the bone marrow? It has been shown that bone marrow–derived endothelial progenitor cells (EPCs) from old animals lose their angiogenic potential. Further, aging decreases the atheroprotective effect of bone marrow–derived CD31*/CD45* stem cells as well as their number in the bone marrow. Finally, aging inhibits EPC mobilization in patients undergoing coronary artery bypass surgery. Do bone marrow–derived cells replenish the CSC pool in the heart throughout life and, similarly to what has been reported for EPCs, do bone marrow–derived “myocardial precursor cells” exhibit an age-dependent decrease in number and deterioration in function before homing to the heart?

Increased p16INK4a expression in old WT mice is in agreement with an impaired CSC proliferative potential; however, this result needs to be reconciled with the increased CSC number in older mice. In fact, increased p16INK4a expression in Bmi1−/− mice was reported to impair self-renewal of stem cells in the neural and hematopoietic systems. Thus, it would be of interest to characterize the CSC population in mice of different ages lacking p16INK4a or its repressor Bmi gene.

Another important finding in Torella’s study is that oxidative stress was enhanced in myocardial cells with a larger cross-sectional area, ie, older myocytes. Since free radical damage may be the mechanism that underlies age-dependent decline in cell function, it will be important to establish the effect of reactive oxygen species on CSCs. There are at least two interesting models in which this question may be addressed. The first model is the p66shc−/− mouse. This transgenic mouse fails to express p66shc adaptor protein, a downstream target of p53 that is necessary for p53 to increase intracellular oxidants and cause cell death. Interestingly, p66shc−/− mice exhibit a life span approximately 30% longer than control and enhanced resistance to oxidative stress. Further, arterial wall oxidative damage, vascular wall cell apoptosis, and early aortic atherosclerotic lesions are attenuated in p66shc−/− mice fed a high-fat diet. The second model is that of caloric restriction. Reduced caloric intake extends maximum life span in a variety of species including nonhuman primates, and it may do so by decreasing oxidative damage. Caloric restriction has specific effects on the heart; it decreases the occurrence and severity of spontaneous age-related cardiomyopathy in rats, it improves diastolic function in old mice, it modifies the pattern of gene expression in the mouse heart, and it increases IGF-1 receptor density in the rat heart.

It is of interest that pRb phosphorylation exhibited an age-dependent decrease in WT mice. This result was explained with enhanced p16INK4a expression; however, enhanced protein phosphatase-2A (PP2A) should also be considered because, in response to oxidative stress, PP2A Rb-bound isoform increases its activity and causes pRb dephosphorylation.

In addition to all the questions that can be raised on the CSC physiopathological role in the aging heart, it is tempting to speculate on CSC potential therapeutic application. If the CSC plays a critical role in preserving myocardial function, would it be possible to use it as a therapeutic tool? Can a CSC from a young heart be used to rejuvenate an old heart? Can a targeted mutation of the p66shc locus make the CSC more resistant to the oxidative damage and enhance its ability to preserve the function of the aging heart? Can IGF-1 or telomerase reverse transcriptase (TERT) gene transfer be applied to the old heart in order to enhance the survival as well as the functional properties of the resident CSC? Recent studies have shown that bone marrow–derived stem cells improve cardiac function after a myocardial infarction. However, there are no data, yet, on the use of stem cells from any origin in the prevention of age-dependent cardiac changes.

As future studies will address the biological significance and therapeutic potential of the CSC in the prevention and treatment of cardiovascular disease in the elderly, it is already apparent that the CSC is a new and important player in this research area.

References


**KEY WORDS:** stem cells, aging, heart, oxidative stress, p66shc.
Cardiac Stem Cells Fail With Aging: A New Mechanism for the Age-Dependent Decline in Cardiac Function
Maurizio C. Capogrossi

Circ Res. 2004;94:411-413
doi: 10.1161/01.RES.0000122070.37999.1B

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/94/4/411

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/